Eylea Manufacturer – About Regeneron Pharmaceuticals

Intravitreal injections have become a cornerstone of modern eye care, with over 7 million procedures performed each year in the U.S. alone. These injections are essential for treating retinal conditions like wet age-related macular degeneration (AMD) and diabetic macular edema, helping millions preserve—and even regain—vision.

At the forefront of this treatment landscape is Eylea, a groundbreaking anti-VEGF therapy developed by Regeneron Pharmaceuticals. Known for its ability to slow disease progression and reduce injection frequency, Eylea has become a go-to option for ophthalmologists and patients alike.

In this article, we’ll take a closer look at Regeneron Pharmaceuticals, the innovative biotech company behind Eylea. From its roots in scientific research to its influence on retinal care, discover how this manufacturer is shaping the future of ophthalmology.

Key Takeaways

• Regeneron Pharmaceuticals, founded in 1988 by Dr. Leonard Schleifer and Dr. George Yancopoulos, is a leading biotechnology company headquartered in Tarrytown, New York. It is focused on translating scientific innovations into life-changing treatments.
• Regeneron’s mission centers on addressing serious medical needs through advanced therapeutics, particularly in ophthalmology, oncology, and inflammatory disorders.
• Regeneron developed Eylea (aflibercept) to treat retinal conditions like wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema post-retinal vein occlusion (RVO) by inhibiting vascular endothelial growth factor (VEGF).
• Eylea received FDA approval in 2011 for wet AMD, with subsequent approvals for additional retinal conditions, significantly impacting ophthalmic treatments.
• Eylea has transformed ophthalmic care by improving patient outcomes, allowing for extended intervals between injections, and, through collaboration with Bayer AG, making it available in over 100 countries worldwide.
• Regeneron continues to research new formulations, gene therapy innovations, and combination therapies to enhance the treatment of retinal diseases and expand Eylea’s therapeutic applications.
• The company prioritizes community engagement through initiatives in STEM education, patient access programs, and environmental sustainability, aligning scientific progress with societal well-being.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to order Eylea online for your practice, contact the Doctor Medica team today.  

History and Mission of Regeneron Pharmaceuticals

Founded in 1988 by Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron Pharmaceuticals began with a bold vision: to turn science into medicine. Headquartered in Tarrytown, New York, the company has grown into a global biotech leader known for translating cutting-edge research into real-world treatments.

Regeneron’s mission is simple yet powerful—harness science to meet serious medical needs. Their research spans across ophthalmology, oncology, immunology, and rare diseases, always with a strong commitment to innovation and patient well-being.

Driven by a robust drug pipeline and continuous investment in R&D, Regeneron has repeatedly demonstrated its dedication to improving lives through groundbreaking medical advances.

Development and Approval of Eylea

One of Regeneron’s most recognized innovations is Eylea (aflibercept)—a treatment developed to manage retinal diseases like wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema from retinal vein occlusion (RVO).

Eylea works by inhibiting vascular endothelial growth factor (VEGF), which helps control abnormal blood vessel growth and fluid leakage in the retina.

In partnership with Bayer for global development, Regeneron secured FDA approval for Eylea in 2011. Since then, its use has expanded to multiple indications across ophthalmology. As with any anti-VEGF treatment, Eylea dosing plays a critical role in ensuring consistent efficacy and long-term results.

Regeneron’s Impact on Ophthalmic Treatments

As the developer of Eylea, Regeneron has reshaped how retinal conditions are treated. The drug’s success lies in its balance between effectiveness and convenience—allowing longer intervals between injections while maintaining strong visual outcomes.

Key contributions of Eylea to the field include:

• Improved Patient Outcomes: Eylea helps prevent vision loss and disease progression in patients with wet AMD and other retinal disorders.
• Extended Treatment Intervals: Many patients can receive injections every 8 to 16 weeks, reducing the frequency of clinic visits.
• Widespread Global Access: With Bayer managing international distribution, Eylea is now available in over 100 countries.

This shift has reduced treatment burdens and improved the quality of life for countless patients worldwide.

Ongoing Research and Future Directions

Regeneron isn’t slowing down. The company continues to explore new frontiers in ophthalmology, aiming to make treatments even more durable, effective, and patient-friendly.

Here’s what’s in the pipeline:

• High-Dose Eylea: Trials are evaluating whether higher doses can further extend treatment intervals without compromising results.
• Gene Therapy: Regeneron is researching gene-based solutions for long-term control of retinal diseases.
• Combination Therapies: Studies are examining the synergy between Eylea and other agents for complex retinal conditions.

Through these efforts, Regeneron strengthens its role as a leader in next-generation eye care.

Corporate Social Responsibility and Community Engagement

Beyond the lab, Regeneron is deeply invested in social impact. Their corporate social responsibility (CSR) initiatives reflect a strong commitment to education, health equity, and sustainability.

Highlights include:

• STEM Education: Sponsorship of initiatives like the Regeneron Science Talent Search nurtures the next generation of scientists.
• Patient Access Programs: Financial assistance initiatives help ensure life-changing medications, like Eylea, are accessible to those who need them most.
• Environmental Sustainability: Regeneron is actively working to lower its carbon footprint and implement eco-friendly practices.

Their commitment to doing good—both scientifically and socially—sets a strong example for the broader healthcare industry.

Conclusion

Regeneron Pharmaceuticals has redefined the standard for ophthalmic care through science, innovation, and compassion. As the manufacturer of Eylea, they’ve helped transform how eye diseases are treated—bringing hope to millions of patients globally.

With a continued focus on research, new therapies, and community engagement, Regeneron is not just shaping the future of retinal care—it’s actively building it.

FAQs

1. What is Eylea used to treat?

Eylea is approved for treating several retinal conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, and macular edema following retinal vein occlusion (RVO). It works by blocking vascular endothelial growth factor (VEGF) to prevent abnormal blood vessel growth and fluid buildup in the retina.

2. Who manufactures Eylea?

Eylea is manufactured by Regeneron Pharmaceuticals, a biotechnology company headquartered in Tarrytown, New York. Bayer AG partners with Regeneron to distribute Eylea in countries outside the United States.

3. Does Regeneron offer other eye treatments?

Yes. Regeneron is actively developing new therapies, including high-dose formulations of Eylea, gene therapy approaches, and combination treatments aimed at improving outcomes and extending the durability of vision care.

References

Wang R, McClard CK, Laswell S, et al. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmology. 2022;7(1):e001188. doi:10.1136/bmjophth-2022-001188

Regeneron Pharmaceuticals. Three-year results for EYLEA HD (aflibercept) injection 8 mg in patients with wet age-related macular degeneration demonstrate continued durable vision gains and anatomic improvement. GlobeNewswire. February 8, 2025. https://www.globenewswire.com/news-release/2025/02/08/3023108/0/en/Three-Year-Results-for-EYLEA-HD-aflibercept-Injection-8-mg-in-Patients-with-Wet-Age-related-Macular-Degeneration-Demonstrate-Continued-Durable-Vision-Gains-and-Anatomic-Improvement.html

Regeneron Pharmaceuticals. EYLEA HD (aflibercept) injection 8 mg positive phase 3 results in diabetic macular edema. Investor Regeneron. February 8, 2025. https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-positive-phase-3-results